abstract |
A cancer therapeutic drug enhanced efficacy and safety is provided. n The cancer therapeutic drug, which is a composition containing α,α,α-trifluorothymidine (FTD) and 5-chloro-6-(1-(2-iminopyrrolidinyl)methyl)uracil hydrochloride in a molar ratio of 1 : 0.5, and which is orally administered to a patient in need thereof at a dose, as a dose of FTD, of 20 to 80 mg/m 2 /day twice daily to four times daily. |